| |
MM
|
NMSC
|
|---|
|
Routine SCS
|
Control
|
Total
|
Routine SCS
|
Control
|
Total
|
|---|
|
n
|
6480
|
7153
|
13,633
|
43,308
|
74,860
|
118,168
|
|
Female sex, %
|
49.4*
|
54.4*
|
52.0
|
51.4*
|
53.5*
|
52.7
|
|
Age: mean (median)
|
63.3* (64.4)
|
66.2* (67.9)
|
64.8 (66.1)
|
70.8* (73.7)
|
74.0* (76.2)
|
72.8 (75.3)
|
|
Elixhauser Comorbidity Index, pre-observation period
|
|
Mean
|
3.14*
|
3.51*
|
3.34
|
3.74*
|
4.13*
|
3.99
|
|
Median
|
3
|
3
|
3
|
3
|
4
|
4
|
|
SD
|
2.63
|
2.74
|
2.69
|
2.70
|
2.78
|
2.76
|
|
Min
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Max
|
16
|
19
|
19
|
18
|
18
|
18
|
|
Pharmacy-based Metric, pre-observation period
|
|
Mean
|
3.20*
|
3.55*
|
3.39
|
3.69*
|
4.07*
|
3.93
|
|
Median
|
3
|
3
|
3
|
3
|
4
|
4
|
|
SD
|
2.36
|
2.47
|
2.42
|
2.39
|
2.47
|
2.45
|
|
Min
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Max
|
14
|
14
|
14
|
16
|
17
|
17
|
- SCS skin cancer screening, SD standard deviation
- *significant difference according to Mann–Whitney-U-test between routine SCS and control, p < 0.05
